Cryoport (CYRX) Investor presentation summary

Market position and growth outlook

• Global leader in temperature-controlled supply chain solutions for the cell & gene therapy (CGT) market, supporting over 65% of active CGT clinical trials and 19 commercial therapies worldwide.

• FY2025 revenue guidance is $170–$174M, with 8–11% organic growth and a gross margin of 55%.

• Services account for 55% of revenue, with a strong presence in the Americas and expanding capabilities in EMEA and APAC.

• The CGT market is projected to grow from $10B in 2025 to $38B by 2030, with clinical trial activity expected to more than double.

• Double-digit services revenue growth and stabilizing product revenue drive significant margin expansion opportunities.

Integrated platform and service offerings

• End-to-end supply chain management includes BioLogistics, IntegriCell®, BioServices, BioStorage, and MVE cryogenic systems.

• BioLogistics provides global, compliant biomaterials handling with real-time tracking and zero-failure transport.

• IntegriCell® delivers standardized collection and cryopreservation for cell therapy starting materials, minimizing variability and improving viability.

• BioServices and BioStorage offer centralized, compliant storage and fulfillment, with scalable biorepository facilities in the US and Europe.

• MVE is the only FDA-registered cryogenic systems manufacturer, serving diverse life sciences sectors.

Digital infrastructure and compliance

• Proprietary Cryoportal® digital platform unifies services, equipment, and data for end-to-end visibility and operational awareness.

• Advanced digital tools enable regulatory reporting, predictive analytics, and real-time monitoring across the cold chain.

• Operations are FDA-registered, GxP-compliant, and aligned with ISO 21973 standards, ensuring full traceability and risk mitigation.